The Scientist

Improving the Efficiency and Reliability of Fully Human Antibody Drug Development

Antibody discovery research paves the way for new therapeutics. The search for the right antibody for a specific therapeutic application necessitates several iterations of antibody production and ...
Business Wire

Biocytogen Announces Licensing of Fully Human Antibodies with SOTIO to Develop Novel ADC SOT109 for Colorectal Cancer Treatment

BEIJING & PRAGUE--(BUSINESS WIRE)--Biocytogen (HKEX: 02315), a global biotech company dedicated to discovering and developing novel antibody therapeutics, announced the licensing of its fully human ...
Business Wire

Biocytogen Secures Japan Patent for RenMab Platform, Expands Global Patent Portfolio for RenMice Fully Human Antibody/TCR Platform

BEIJING--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315) today announced that the key technology of its independently developed RenMab™ fully human antibody ...
Morningstar

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with ...
Nasdaq

Sonnet BioTherapeutics Secures European Patent for Fully Human Albumin Binding Technology, Expanding Global IP Coverage

EPO grants Sonnet EU Patent No. EP3583125 B1 for Fully Human Albumin Binding (FHAB®) domain fusion proteins, expanding global IP protection. Sonnet BioTherapeutics Holdings, Inc. announced that the ...